A new startup wants to take antisense and siRNA one step further, and build more potent drugs than Ionis and Alnylam
Drugging RNA has become a hot biopharma topic in recent years, particularly after the massive successes of the Covid-19 vaccines. But one biotech is aiming to take things a step further, utilizing the single-stranded molecules before they even become RNA.
Ceptur Therapeutics launched Wednesday morning with a $75 million Series A, the company announced. The goal is to push forward a slate of oligonucleotide-based therapies that can control gene expression, and even silence some targeted genes, at the “pre-mRNA level,” co-founder and CEO Peter Ghoroghchian told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.